Punjab-based Parabolic Drugs (PDL), a leading research based active pharmaceutical ingredients manufacturer on Monday said that it has received European Union (EU) approval for its Cephalasporin’s manufacturing facility in Derabassi near here.
Executive director, PDL, Vineet Gupta told that the 27 acre Cephalosporin API?s and intermediates manufacturing unit was inspected by German Auditors in April and was found to be compliant with the principles of GMP (EU-GMP ? Part II) for active substances. The company has received approval for three of its molecules ? namely, Cefuroxime Axetil, Cefpodoxime Proxetil and Cefixime Trihydrate. This will enable the company to sell its products in Europe, Canada and Australian markets, thus giving a boost to company?s vision of building its business in regulated markets. ?Parabolic already has a USFDA approval for selling one of its products in the US markets from its Panchkula facilit, he added.